

# Keith D Eaton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12064/publications.pdf>

Version: 2024-02-01

57  
papers

9,749  
citations

257450

24  
h-index

175258

52  
g-index

57  
all docs

57  
docs citations

57  
times ranked

17345  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Impact of Diagnostic Delays on Lung Cancer Survival Outcomes: A Population Study of the US SEER-Medicare Database. <i>JCO Oncology Practice</i> , 2022, 18, e877-e885.   | 2.9 | 4         |
| 2  | Performance status (<scp>PS</scp>) as a predictor of poor response to immune checkpoint inhibitors (<scp>ICI</scp>) in recurrent/metastatic head and neck cancer (<scp>RMHNSCC</scp>) patients. <i>Cancer Medicine</i> , 2022, 11, 4104-4111.  | 2.8 | 11        |
| 3  | A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100416. | 1.7 | 0         |
| 4  | Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 523-530.  | 2.6 | 4         |
| 5  | Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1225-e1234.  | 2.9 | 3         |
| 6  | A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101541.   | 0.4 | 5         |
| 7  | Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e18804.   | 0.5 | 0         |
| 8  | High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Palliative Medicine</i> , 2021, , .  | 1.1 | 0         |
| 9  | Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institution. <i>Oral Oncology</i> , 2021, 123, 105626.  | 1.5 | 1         |
| 10 | A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 837-845.  | 7.0 | 120       |
| 11 | Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.   |     | 30        |
| 12 | <i>MYCN</i> drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. <i>Genes and Development</i> , 2020, 34, 1210-1226.   | 5.9 | 46        |
| 13 | Aldosterone-Secreting Adrenocortical Carcinoma Presenting With Cardiac Arrest. <i>Journal of the Endocrine Society</i> , 2019, 3, 1678-1681.   | 0.2 | 2         |
| 14 | Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. <i>Science Signaling</i> , 2019, 12, .   | 3.6 | 130       |
| 15 | Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome. <i>BMC Cancer</i> , 2019, 19, 70.                                | 2.6 | 6         |
| 16 | Sarcoidosis Presenting as Isolated Anasarca and Hypercalcemia. <i>American Journal of Medicine</i> , 2019, 132, e13-e14.   | 1.5 | 0         |
| 17 | Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. <i>Cancer</i> , 2018, 124, 2841-2849.                              | 4.1 | 7         |
| 18 | Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. <i>Journal of Thoracic Oncology</i> , 2018, 13, 649-659.  | 1.1 | 35        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 836-847.  | 2.6 | 63        |
| 20 | Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. <i>Head and Neck</i> , 2018, 40, 584-589.  | 2.0 | 13        |
| 21 | Pregnancy Screening in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 99-103.  | 4.9 | 4         |
| 22 | Characterizing Potentially Preventable Cancer- and Chronic Disease-Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. <i>Journal of Oncology Practice</i> , 2018, 14, e176-e185.                                 | 2.5 | 74        |
| 23 | An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). <i>Lung Cancer</i> , 2017, 104, 126-130.  | 2.0 | 33        |
| 24 | Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN. <i>Clinical Cancer Research</i> , 2017, 23, 2442-2450.   | 7.0 | 102       |
| 25 | Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1583-1588.   | 2.0 | 8         |
| 26 | Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 145-151.  | 1.1 | 48        |
| 27 | Phase 2 Study of Erlotinib in Combination With Afatinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 34-42.e2. | 2.6 | 29        |
| 28 | Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience. <i>Head and Neck</i> , 2016, 38, 1318-1323.   | 2.0 | 12        |
| 29 | Value-Based Care in Lung Cancer. <i>Oncologist</i> , 2016, 21, 903-906.  | 3.7 | 12        |
| 30 | Spontaneous Regression of Non-Small-Cell Lung Cancer in AIDS After Immune Reconstitution. <i>Journal of Thoracic Oncology</i> , 2015, 10, e1-e2.   | 1.1 | 10        |
| 31 | Detection of HPV in oral rinse samples from OPSCC and non-OPSCC patients. <i>BMC Oral Health</i> , 2015, 15, 126.  | 2.3 | 17        |
| 32 | The Pseudocavitation Sign of Lung Adenocarcinoma. <i>Journal of Thoracic Imaging</i> , 2015, 30, 308-313.  | 1.5 | 17        |
| 33 | Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation. <i>American Journal of Clinical Pathology</i> , 2015, 144, 263-270.  | 0.7 | 10        |
| 34 | Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, e137-e138.  | 8.6 | 138       |
| 35 | Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. <i>Oncologist</i> , 2014, 19, 175-176.                            | 3.7 | 21        |
| 36 | Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 56-67.        | 2.8 | 234       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Occult Primary, Version 3.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 969-974.  | 4.9  | 27        |
| 38 | Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. Journal of Clinical Oncology, 2013, 31, 1415-1421.                                       | 1.6  | 180       |
| 39 | EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers. Journal of Thoracic Oncology, 2013, 8, e6-e7.  | 1.1  | 11        |
| 40 | Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels. PLoS ONE, 2013, 8, e64795.   | 2.5  | 258       |
| 41 | Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy. Cancers, 2012, 4, 969-988.  | 3.7  | 45        |
| 42 | Is There a Role for Whole Brain Radiotherapy in the Treatment of Leptomeningeal Metastases?. Journal of Thoracic Oncology, 2012, 7, 1204.  | 1.1  | 7         |
| 43 | A 66-Year-Old Woman With Newly Diagnosed Oligometastatic Non-Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 297-301.   | 4.9  | 1         |
| 44 | A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer, 2012, 12, 449.   | 2.6  | 26        |
| 45 | Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.  | 27.0 | 6,820     |
| 46 | Occult Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1358-1395.   | 4.9  | 41        |
| 47 | Radiation-Induced Myelopathy. Archives of Neurology, 2011, 68, 1608.   | 4.5  | 25        |
| 48 | Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer. World Journal of Oncology, 2011, 2, 64-69.   | 1.5  | 1         |
| 49 | Maintenance Chemotherapy in Non-Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 815-821.   | 4.9  | 27        |
| 50 | Intradural intramedullary spinal cord metastasis due to mesothelioma. Journal of Neuro-Oncology, 2010, 97, 133-136.  | 2.9  | 24        |
| 51 | Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 3076-3083.                                 | 1.6  | 402       |
| 52 | Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation. Clinical Cancer Research, 2010, 16, 5260-5268. | 7.0  | 389       |
| 53 | Cancer pain: Perspectives of a medical oncologist. Current Pain and Headache Reports, 2008, 12, 270-276.   | 2.9  | 3         |
| 54 | Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. Annals of Thoracic Surgery, 2008, 86, 1632-1639.   | 1.3  | 96        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Occult Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 1026.   | 4.9 | 2         |
| 56 | Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab. Archives of Dermatology, 2007, 143, 889-92.  | 1.4 | 92        |
| 57 | Antagonism of Platelet-Derived Growth Factor Receptor in Nonâ€“Small Cell Lung Cancer: Rationale and Investigations. Clinical Cancer Research, 2007, 13, 4632s-4636s. | 7.0 | 23        |